Talis Biomedical (NASDAQ:TLIS) and Bionano Genomics (NASDAQ:BNGO) Critical Comparison

Talis Biomedical (NASDAQ:TLIS) and Bionano Genomics (NASDAQ:BNGO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations.

Institutional and Insider Ownership

81.6% of Talis Biomedical shares are held by institutional investors. Comparatively, 15.5% of Bionano Genomics shares are held by institutional investors. 0.6% of Bionano Genomics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Talis Biomedical and Bionano Genomics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Talis Biomedical $10.94 million 24.28 -$91.13 million N/A N/A
Bionano Genomics $8.50 million 257.20 -$41.11 million ($0.39) -20.10

Bionano Genomics has lower revenue, but higher earnings than Talis Biomedical.

Analyst Ratings

This is a summary of recent ratings and price targets for Talis Biomedical and Bionano Genomics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talis Biomedical 0 1 3 0 2.75
Bionano Genomics 0 1 3 0 2.75

Talis Biomedical currently has a consensus target price of $15.75, indicating a potential upside of 52.03%. Bionano Genomics has a consensus target price of $10.08, indicating a potential upside of 28.61%. Given Talis Biomedical’s higher probable upside, equities research analysts clearly believe Talis Biomedical is more favorable than Bionano Genomics.

Profitability

This table compares Talis Biomedical and Bionano Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Talis Biomedical N/A N/A N/A
Bionano Genomics -384.80% -40.47% -32.94%

Summary

Talis Biomedical beats Bionano Genomics on 6 of the 9 factors compared between the two stocks.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company. It is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. The company is also developing Talis One assay kits for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A and influenza B plus SARS-CoV-2. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.

About Bionano Genomics

Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Receive News & Ratings for Talis Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talis Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.